19-412 - A Study of Brentuximab Vedotin in Adults Age 60 and Above With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)Status: open
A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Treatment for Hodgkin Lymphoma
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by email at firstname.lastname@example.org.
The trial will study brentuximab vedotin to find out whether it is an effective treatment in patients 60 years or older for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). The study will look at brentuximab vedotin alone and combined with other drugs.
SponsorsThis trial is sponsored by Seattle Genetics.
Providers Associated With This Trial
- Omar Alkharabsheh, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology; Associate Program Director, Medical Oncology Fellowship